Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

Partner | Cancer Centers | <b>MD Anderson</b>

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma (MCL).

The ZUMA-2 trial included patients with relapsed/refractory MCL who had received at least 1 prior BTK inhibitor, says Wang. Patients could have relapsed on ibrutinib (Imbruvica), acalabrutinib (Calquence), or both.

The multicenter trial enrolled 74 patients, 68 of which received conditioning treatment and an infusion of the investigational CAR T-cell therapy KTE-X19, says Wang. Among those patients, investigators reported a 93% overall response rate and a 67% complete response rate.

After a median follow-up of 12.3 months, progression-free survival, overall survival, and duration of response were not reached. Among the first 28 patients treated on the trial, the median follow-up was 27 months. Nearly half of these patients remained in remission, suggesting KTE-X19 can elicit durable responses, concludes Wang.